pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,187 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1164Endpoints880BioPharma Dive340BioSpace299Fierce Biotech280onclive165raps104globenewswire health73
therapy area
allOncology7479Rare Disease1850Cardiology1689Immunology1471Hematology1313Vaccines1190Pulmonology
  • General Catalyst uses Summa Health as test bed for AI-driven patient support tools
    General Catalyst bought Ohio safety‑net hospital Summa Health in October and is using it to trial new health‑technology tools. Executives from the holding company, Health Assurance Transformation C…
    STAT · 3mo agoPositive↗ source
  • Trump administration issues rules for Medicaid work requirements
    The Centers for Medicare and Medicaid Services released a rule that sets out the standards states must follow to enforce new Medicaid work requirements. The rule details who qualifies for exemptio…
    STAT · 3mo agoRegulatoryNeutral↗ source
← prev
page 72 of 88
next →
fda recalls67
fda medwatch60
fda press38
1122
Psychiatry & CNS862
Ophthalmology494
Pain473
Endocrinology & Metabolism466
Infectious Disease444
  • RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo Therapeutics
    RallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
    BioPharma Dive · 3mo agoDealNeutral↗ source
  • Croatian researcher’s five-decade quest to uncover BPC-157’s potential draws FDA attention
    In 1975 a second‑year medical student at the University of Zagreb heard a lecture on stress and the stomach lining. He imagined the organ produced a natural anti‑stress chemical and set out to find…
    STAT · 3mo agoNeutral↗ source
  • FDA misses self-imposed deadline on electric shock device ban, prompting disability advocates' outcry
    The Food and Drug Administration did not issue a decision by the end of May as it had set for itself on whether to prohibit electrical shock devices used on people with intellectual disabilities an…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Hospitals grapple with patient requests for unvaccinated donor blood
    Some patients are now asking hospitals to provide blood that comes only from donors who have not received any COVID-19 vaccine, creating a new set of ethical and logistical questions. The demand r…
    STAT · 3mo agoNeutral↗ source
  • New No Surprises Act arbitration rule may increase provider disputes, critics say
    The administration released a final rule on Thursday that tweaks the No Surprises Act arbitration process. The changes are meant to improve communication between insurers and providers and give Med…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Residency dismissals disproportionately affect Black and Latino trainees despite medical school diversification
    Medical schools have made notable progress in diversifying their student bodies, with enrollment of Black and Latino students rising over the past decade through pipeline programs, scholarships, an…
    STAT · 3mo agoNegative↗ source
  • Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial, Study Shows
    Results from a late-stage trial of the experimental pill daraxonrasib were presented at the American Society of Clinical Oncology meeting. The data showed that patients receiving the drug lived alm…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trial
    Data presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLC
    Data presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Phase 3 trial shows pre- and post-surgery hormone therapy improves outcomes for high-risk prostate cancer
    A phase 3 study called PROTEUS evaluated high‑risk, early‑stage prostate cancer patients who were scheduled for surgery. The trial compared a regimen that gave two hormone therapies before and afte…
    STAT · 3mo agoPositive readoutPositive↗ source
  • RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces caution
    At the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation. In contrast, presentations fro…
    STAT · 3mo agoNeutral↗ source
  • Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in India
    Researchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survival
    A trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
    BioPharma Dive · 3mo agoPositive readoutNeutral↗ source
  • Revolution Medicines begins shipping experimental pancreatic cancer drug daraxonrasib under FDA early access program
    Revolution Medicines announced that it has started sending its experimental pancreatic cancer therapy, daraxonrasib, to doctors and patients through an FDA‑authorized early access program. The comp…
    STAT · 3mo agoRegulatoryPositive↗ source
  • BioNTech and Pfizer present bispecific cancer data at ASCO, FDA chief notes optimism
    At the American Society of Clinical Oncology meeting, BioNTech and Pfizer highlighted early results from bispecific antibody programs aimed at lung cancer. The companies described the data as promi…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Former FDA oncology chief says political turmoil opens chance to reshape agency amid rising Chinese competition
    Rick Pazdur, who led oncology reviews at the FDA, told a STAT audience at the American Society of Clinical Oncology meeting that recent political appointments have caused significant disruption at…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Trump administration abandons Biden Ebola response plan, opting for new strategy
    The Biden administration completed a multi-hundred-page set of guidelines in early 2025 outlining how federal agencies should handle future disease threats, including protocols for Ebola outbreaks…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Bristol Myers reports Phase 3 data showing mezigdomide extends survival in relapsed multiple myeloma
    Bristol Myers Squibb presented Phase 3 results for its experimental multiple myeloma drug mezigdomide at the American Society of Clinical Oncology meeting. The study evaluated mezigdomide combined…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Pfizer partners with China's Innovent Biologics on $10 billion cancer drug collaboration
    Pfizer announced a major partnership with Chinese biotech Innovent Biologics, valued at over $10 billion, to develop cancer therapies. The agreement covers up to 12 antibody-based candidates, incl…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCO
    Merck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCO
    At the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the in…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Trump administration proposes overhaul of federal grant rules, sparking researcher concerns
    The White House released a more than 400-page proposal that would rewrite the core regulation governing all federal grants. The administration says the changes are meant to curb waste and increase…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Replimune to file third FDA application for RP1 cancer therapy after productive talks
    Replimune announced it will submit a third marketing application for its experimental cancer therapy RP1, following what the company described as productive discussions with the Food and Drug Admin…
    BioPharma Dive · 3mo agoApprovalPositive↗ source